title: Hepatorenal syndrome after treatment of visceral leishmaniasis requiring terlipressin therapy.
authors.affiliation: Division on Gastroenterology and Hepatology, San Giovanni Battista Hospital, University of Turin, Turin, Italy - marco.sacco10@gmail.com.
authors.forename: A
authors.initials: A
authors.lastname: Marzano
authors.forename: W
authors.initials: W
authors.lastname: Debernardi Venon
authors.forename: M
authors.initials: M
authors.lastname: Sacco
authors.forename: M
authors.initials: M
authors.lastname: Rizzetto
mesh_terms: D000328:Adult; D000666:Amphotericin B / Q000009:adverse effects*; D000981:Antiprotozoal Agents / Q000009:adverse effects*; D006530:Hepatorenal Syndrome / Q000139:chemically induced* / Q000188:drug therapy; D006801:Humans; D007898:Leishmaniasis, Visceral / Q000188:drug therapy*; D008236:Lypressin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D000077585:Terlipressin; D014662:Vasoconstrictor Agents / Q000627:therapeutic use*
chemical_list: D000981:Antiprotozoal Agents; D014662:Vasoconstrictor Agents; C068538:liposomal amphotericin B; D008236:Lypressin; D000666:Amphotericin B; D000077585:Terlipressin